Keyvan Rezaï

3.5k total citations · 2 hit papers
78 papers, 2.3k citations indexed

About

Keyvan Rezaï is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Keyvan Rezaï has authored 78 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 32 papers in Oncology and 19 papers in Hematology. Recurrent topics in Keyvan Rezaï's work include Protein Degradation and Inhibitors (20 papers), Multiple Myeloma Research and Treatments (16 papers) and HER2/EGFR in Cancer Research (11 papers). Keyvan Rezaï is often cited by papers focused on Protein Degradation and Inhibitors (20 papers), Multiple Myeloma Research and Treatments (16 papers) and HER2/EGFR in Cancer Research (11 papers). Keyvan Rezaï collaborates with scholars based in France, United States and Switzerland. Keyvan Rezaï's co-authors include François Lokiec, Gordon M. Trenholme, Miguel G. Madariaga, Robert A. Weinstein, Patrice Herait, Anastasios Stathis, Mohamed Békradda, Carmen Kahatt, María E. Riveiro and Esteban Cvitkovic and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Keyvan Rezaï

75 papers receiving 2.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

2016 336 citations Céline Berthon, Emmanuel Raffoux et al. The Lancet Haematology profile →
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

2016 328 citations Anastasios Stathis, Keyvan Rezaï et al. The Lancet Haematology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Keyvan Rezaï	1.5k	640	499	187	176	78	2.3k
Marianne Kraus	1.4k 0.9×	614 1.0×	537 1.1×	88 0.5×	134 0.8×	48	2.2k
Christina Kunz	607 0.4×	334 0.5×	234 0.5×	54 0.3×	97 0.6×	57	1.4k
Glenn M. Swartz	975 0.7×	175 0.3×	333 0.7×	36 0.2×	92 0.5×	40	2.1k
Isabelle Rooney	1.0k 0.7×	219 0.3×	618 1.2×	52 0.3×	104 0.6×	49	2.5k
E. J. B. M. Mensink	728 0.5×	605 0.9×	407 0.8×	74 0.4×	46 0.3×	52	1.9k
Annkristin Heine	1.0k 0.7×	423 0.7×	662 1.3×	28 0.1×	208 1.2×	66	2.4k
Scott Presnell	999 0.7×	714 1.1×	245 0.5×	26 0.1×	164 0.9×	35	2.7k
Connie M. Arthur	1.4k 1.0×	830 1.3×	237 0.5×	44 0.2×	174 1.0×	98	3.0k
Jeffrey J. Bednarski	906 0.6×	99 0.2×	264 0.5×	120 0.6×	56 0.3×	53	1.6k
Gregory R. Johnson	822 0.5×	719 1.1×	449 0.9×	34 0.2×	46 0.3×	55	2.4k

Countries citing papers authored by Keyvan Rezaï

Since Specialization

Citations

This map shows the geographic impact of Keyvan Rezaï's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keyvan Rezaï with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keyvan Rezaï more than expected).

Fields of papers citing papers by Keyvan Rezaï

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keyvan Rezaï. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keyvan Rezaï. The network helps show where Keyvan Rezaï may publish in the future.

Co-authorship network of co-authors of Keyvan Rezaï

This figure shows the co-authorship network connecting the top 25 collaborators of Keyvan Rezaï. A scholar is included among the top collaborators of Keyvan Rezaï based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keyvan Rezaï. Keyvan Rezaï is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Reinhold, William C., Elisabetta Marangoni, Fathi Elloumi, et al.. (2025). Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study. Cancer Research Communications. 5(2). 375–388. 1 indexed citations

Huguet, Samuel, et al.. (2022). Application of an Environmental Monitoring to Assess the Practices and Control the Risk of Occupational Exposure to Cyclophosphamide in Two Sites of a French Comprehensive Cancer Center. Annals of Work Exposures and Health. 66(9). 1215–1223. 10 indexed citations

Sestito, Simona, Massimiliano Runfola, Francesca Gado, et al.. (2021). Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile. European Journal of Medicinal Chemistry. 226. 113895–113895. 8 indexed citations

Huguet, Samuel, et al.. (2021). Ultra‐fast liquid chromatography method coupled with ultraviolet detection to quantify dimethylsulfoxide, dimethylformamide and dimethylacetamide in short half‐lives radiopharmaceuticals. Journal of Labelled Compounds and Radiopharmaceuticals. 64(11). 440–446. 2 indexed citations

Huguet, Samuel, et al.. (2021). Single radio UHPLC analysis for the quality control of technetium-99m radiolabelled radiopharmaceuticals. Applied Radiation and Isotopes. 176. 109874–109874. 5 indexed citations

Peta, Valentina, Jianhui Zhu, David M. Lubman, et al.. (2020). Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease. Clinics and Research in Hepatology and Gastroenterology. 44(5). 681–691. 8 indexed citations

Tarantelli, Chiara, Elena Bernasconi, Eugenio Gaudio, et al.. (2018). BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. ESMO Open. 3(6). e000387–e000387. 21 indexed citations

Guérin, Mathilde, Keyvan Rezaï, Nicolás Isambert, et al.. (2017). PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. European Journal of Cancer. 86. 28–36. 45 indexed citations

Gérard, Camille L., et al.. (2017). Permeability and Release of Decontaminating Agent Used in Cytotoxic Reconstitution Units: Diffusion of Hydrogen Peroxide in IV Bags. SHILAP Revista de lepidopterología. 2(1). 1 indexed citations

10.

Astorgues‐Xerri, Lucile, Elodie Odore, Esteban Cvitkovic, et al.. (2016). OTX015 (MK‐8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. International Journal of Cancer. 139(9). 2047–2055. 122 indexed citations

11.

Berthon, Céline, Emmanuel Raffoux, Xavier Thomas, et al.. (2016). Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. The Lancet Haematology. 3(4). e186–e195. 336 indexed citations breakdown →

12.

Campone, Mario, Jean‐Louis Merlin, Valérie Gouilleux‐Gruart, et al.. (2015). Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non‐metastatic breast cancer. British Journal of Clinical Pharmacology. 81(5). 941–948. 25 indexed citations

13.

Fumoleau, P., Kevin M. Koch, Étienne Brain, et al.. (2014). A phase I pharmacokinetics study of lapatinib and tamoxifen in metastatic breast cancer (EORTC 10053 Lapatam study). The Breast. 23(5). 663–669. 10 indexed citations

14.

Barreiro, Luis B., Sylvère Durand, Guillaume Soubigou, et al.. (2014). Extracellular Adenosine Triphosphate Affects the Response of Human Macrophages Infected With Mycobacterium tuberculosis. The Journal of Infectious Diseases. 210(5). 824–833. 17 indexed citations

15.

Lokiec, François, et al.. (2012). Adaptation of methotrexate determination in serum with Unicel DxC600®. Annales de biologie clinique. 70(3). 277–286. 3 indexed citations

16.

Rezaï, Keyvan, Saı̈k Urien, Nicolás Isambert, et al.. (2011). Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients. Cancer Chemotherapy and Pharmacology. 68(6). 1529–1536. 18 indexed citations

17.

Ourliac‐Garnier, Isabelle, Anaïs Poulet, Simon Amiard, et al.. (2010). Platination of telomeric DNA by cisplatin disrupts recognition by TRF2 and TRF1. JBIC Journal of Biological Inorganic Chemistry. 15(5). 641–654. 10 indexed citations

18.

Gligorov, Joseph, Frédèric Selle, Éric Levy, et al.. (2007). ABCB1 (MDR1) genotype in relation to doxorubicin and docetaxel pharmacokinetics in patients with breast cancer. Cancer Research. 67. 729–729. 1 indexed citations

19.

Brain, Étienne, Keyvan Rezaï, B. Besse, et al.. (2006). Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study. Cancer Chemotherapy and Pharmacology. 60(3). 375–381. 9 indexed citations

20.

Chong, Anita S., Keyvan Rezaï, Howard M. Gebel, et al.. (1996). EFFECTS OF LEFLUNOMIDE AND OTHER IMMUNOSUPPRESSIVE AGENTS ON T CELL PROLIFERATION IN VITRO1. Transplantation. 61(1). 140–145. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact